There are currently 2695 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
NCT05287451
Recruiting
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Harvard Cancer Center, Boston, Massachusetts
Conditions: Ovarian Cancer, Fallopian Tube Cancer
Register for Updates
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880
Recruiting
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
01/09/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sickle Cell Disease
Register for Updates
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
NCT04047251
Recruiting
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute (DFCI), Boston, Massachusetts
Conditions: Advanced Solid Tumors, Merkel Cell Carcinoma
Register for Updates
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
NCT04583878
Recruiting
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
01/09/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
NCT03709758
Recruiting
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: * Venetoclax * Daunorubicin * Cytarabine
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Tufts Medical Center, Boston, Massachusetts +3 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT06015659
Recruiting
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nucleoside metabolic inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399
Recruiting
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/09/2025
Locations: Research Site, Boston, Massachusetts +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Conventional Chondrosarcoma
Register for Updates
Testimonials and Navigation in Rheumatology
NCT06469788
Recruiting
The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Brigham Women's Hospital, Boston, Massachusetts
Conditions: Rheumatologic Disease, Autoimmune Diseases
Register for Updates
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease
NCT05776641
Recruiting
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
01/08/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Alzheimer Disease, Family Members
Register for Updates
Just-in-time Interventions for Reducing Short-term Suicide Risk
NCT05793541
Recruiting
The goal of this study is to test the effects of just-in-time intervention strategies aimed to promote implementation of the safety plan and its components at different levels of suicidal urges and intent. The main questions the investigators aim to answer are: 1. What is the acceptability and feasibility of the just-in-time intervention strategies? 2. What are the proximal effects of just-in-time intervention strategies aimed to promote use of the safety plan and its components? 3. What intern... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Mass General Brigham, Boston, Massachusetts
Conditions: Suicide
Register for Updates